Targeting specific tumors to enhance immune response against cancer
Targeting NQO1+ tumor to trigger innate and adaptive immunity
This study is looking at a new cancer treatment using a drug called β-Lapachone that targets tumors with a specific protein, aiming to boost the immune system and work better with current therapies for patients with certain types of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-10861098 on NIH RePORTER |
What this research studies
This research focuses on developing new cancer treatments that specifically target tumors with high levels of a protein called NQO1. The approach involves using a drug called β-Lapachone, which activates in these tumors to produce reactive oxygen species that damage cancer cells and stimulate the immune system. The study aims to understand how this drug can trigger immune responses and work alongside existing immunotherapies to improve treatment outcomes for patients with certain types of cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that exhibit elevated levels of NQO1.
Not a fit: Patients whose tumors do not express high levels of NQO1 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that harness the body's immune system to fight tumors.
How similar studies have performed: Previous research has shown promise in using similar approaches to enhance immune responses against tumors, indicating potential for success in this area.
Where this research is happening
Indianapolis, United States
- Indiana University Indianapolis — Indianapolis, United States (Active)
Researchers
- Principal investigator: Huang, Xiumei — Indiana University Indianapolis
- Study coordinator: Huang, Xiumei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.